Related Experiment Video

Updated: Apr 5, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure

Marcello Maida1, Massimo Iavarone1, Maurizio Raineri1

  • 1Marcello Maida, Calogero Cammà, Giuseppe Cabibbo, Section of Gastroenterology, DIBIMIS, University of Palermo, 90127 Palermo, Italy.

World Journal of Hepatology
|August 25, 2015
PubMed

Insights

Advanced hepatocellular carcinoma (HCC) treatments like sorafenib face challenges. New first-line and second-line therapies for HCC are urgently needed, as recent trials show limited success.

Area of Science:

  • Hepatology
  • Oncology
  • Clinical Trials

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of death in cirrhosis patients, with rising global incidence.
  • Sorafenib is the standard first-line treatment for advanced HCC.
  • Numerous clinical trials comparing sorafenib with other agents as first-line therapy have yielded no new registered treatments.

Purpose of the Study:

  • To analyze the reasons behind the failure of tested molecules in advanced HCC.
  • To discuss the future outlook for advanced HCC treatment, particularly in the second-line setting.

Main Methods:

  • Review of randomized phase III trials for advanced HCC.
  • Analysis of clinical trial outcomes comparing sorafenib with other first-line agents.
  • Evaluation of second-line therapy trials for advanced HCC post-sorafenib failure.

Main Results:

  • No alternative first-line treatments have been registered for advanced HCC compared to sorafenib.
  • All tested second-line therapies for advanced HCC have failed to show improved survival over placebo.
  • There is a significant unmet medical need for effective second-line treatments after sorafenib failure.

Conclusions:

  • The failure of multiple drug candidates in advanced HCC trials necessitates a re-evaluation of treatment strategies.
  • Understanding the reasons for these failures is crucial for developing future effective therapies for hepatocellular carcinoma.
Keywords:
Barcelona Clinic Liver CancerHepatocellular carcinomaSorafenibSystemic therapies

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
337